BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35028141)

  • 21. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
    Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes.
    Dargent JL; Mathieux V; Vidrequin S; Deghorain X; Vannuffel P; Rack K
    Eur J Haematol; 2011 Jan; 86(1):87-90. PubMed ID: 21070368
    [No Abstract]   [Full Text] [Related]  

  • 23. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11).
    Chamseddine AN; Etancelin P; Penther D; Parmentier F; Kuadjovi C; Camus V; Contentin N; Lenain P; Bastard C; Tilly H; Jardin F
    Case Rep Hematol; 2015; 2015():252537. PubMed ID: 25789185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of
    Zhang L; Zhu X; Qu W; Lu Y; Feng Z; Zhao L
    Haematologica; 2023 Dec; 108(12):3506-3510. PubMed ID: 37102606
    [No Abstract]   [Full Text] [Related]  

  • 27. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
    Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
    Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
    Rumi E; Milosevic JD; Selleslag D; Casetti I; Lierman E; Pietra D; Cavalloni C; Bellini M; Milanesi C; Dambruoso I; Astori C; Kralovics R; Vandenberghe P; Cazzola M
    Ann Hematol; 2015 Nov; 94(11):1927-8. PubMed ID: 26202607
    [No Abstract]   [Full Text] [Related]  

  • 29. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
    Bain BJ; Ahmad S
    Br J Haematol; 2014 Sep; 166(6):809-17. PubMed ID: 24913195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
    Cheng Q; Tang Y; Liu F; Li X; Fang D
    Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).
    Nakamura F; Seo S; Nannya Y; Ayabe R; Takahashi W; Handa T; Arai H; Iso H; Nakamura Y; Nakamura Y; Sasaki K; Ichikawa M; Imai Y; Ogawa S; Mitani K
    Int J Hematol; 2023 Sep; 118(3):388-393. PubMed ID: 36930401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
    Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
    Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
    Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
    Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
    [No Abstract]   [Full Text] [Related]  

  • 35. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of
    Zhang XY; Dai HP; Li Z; Yin J; Lang XP; Yang CX; Xiao S; Zhu MQ; Liu DD; Liu H; Shen HJ; Wu DP; Tang XW
    Front Oncol; 2020; 10():611467. PubMed ID: 33505919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
    Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
    Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
    Smith CA; Fan G
    Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
    Peeters P; Raynaud SD; Cools J; Wlodarska I; Grosgeorge J; Philip P; Monpoux F; Van Rompaey L; Baens M; Van den Berghe H; Marynen P
    Blood; 1997 Oct; 90(7):2535-40. PubMed ID: 9326218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia.
    Haslam K; Langabeer SE; Kelly J; Coen N; O'Connell NM; Conneally E
    Case Rep Hematol; 2012; 2012():620967. PubMed ID: 23082258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.